According to @StockMKTNewz, Hims & Hers Health (HIMS) said it is in active discussions with Novo Nordisk (NVO) to sell its GLP-1 weight-loss therapy Wegovy as well as a pill version of the medicine that is still in development. Source: @StockMKTNewz; Seeking Alpha. The report specifies that both the injectable Wegovy and a forthcoming oral formulation are included in the discussions, highlighting potential distribution expansion if an agreement is reached. Source: @StockMKTNewz; Seeking Alpha. The source did not reference any direct cryptocurrency market impact from this update. Source: @StockMKTNewz; Seeking Alpha.